7 May 2025 (34 Days) Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | 0.12 Cons. EPS | 0.09 EPS |
14 Nov 2024 Date | | - Cons. EPS | 0.07 EPS |
7 Nov 2024 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | 0.02 Cons. EPS | 0.1 EPS |
7 May 2025 (34 Days) Date | | - Cons. EPS | - EPS |
6 Feb 2025 Date | | 0.12 Cons. EPS | 0.09 EPS |
14 Nov 2024 Date | | - Cons. EPS | 0.07 EPS |
7 Nov 2024 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | 0.02 Cons. EPS | 0.1 EPS |
Medical Devices Industry | Healthcare Sector | Mr. Joseph C. Sardano CEO | NASDAQ (CM) Exchange | US81728J1097 ISIN |
US Country | 35 Employees | - Last Dividend | - Last Split | 3 Jun 2016 IPO Date |
Sensus Healthcare, Inc. stands as a prominent medical device company dedicated to the production and global distribution of radiation therapy devices aimed at healthcare providers. Founded in 2010 with its headquarters in Boca Raton, Florida, the company leverages the power of superficial radiation therapy—a low-energy X-ray technology—across its suite of treatment devices. This innovative approach positions Sensus Healthcare at the forefront of providing non-surgical alternative treatments for non-melanoma skin cancers, including basal cell and squamous cell carcinomas, along with other skin conditions like keloids. Their commitment to advancing non-invasive treatment options underlines their significant role within both private dermatology practices and radiation oncology sectors in various healthcare settings.
The SRT-100 is a flagship product, offering a photon X-ray low energy superficial radiotherapy system designed for the treatment of non-melanoma skin cancers and various skin conditions, such as keloids. It provides a viable alternative to surgical treatments, emphasizing patient comfort and recovery.
Building upon the foundation laid by the SRT-100, the SRT-100 Vision incorporates advanced features, including a treatment planning application tailored for superficial radiation therapy. This system is enhanced with an embedded high frequency ultrasound imaging module, enabling volumetric tumor analysis, precise beam margins planning, and detailed dosimetry parameters to optimize treatment efficacy.
An extension of the SRT product line, the SRT-100 Plus continues to support the non-surgical treatment landscape with improvements in efficiency and patient outcomes, showcasing Sensus Healthcare's commitment to innovation and excellence in skin cancer treatment.
This service program demonstrates Sensus Healthcare's dedication to customer support by offering comprehensive protection plans for their systems. It ensures that healthcare providers can continually deliver high-quality care with the assurance of reliable system performance and maintenance.
A pioneering biophysical approach for the non-invasive transfer of high weight molecule modalities into the dermis. This needle-free system is designed for both medical and aesthetic purposes, broadening the scope of treatment possibilities to include a variety of skin conditions and aesthetic treatments.
In addition to its SRT product line, Sensus Healthcare diversifies its portfolio by distributing laser devices suitable for a range of dermatological applications. These include hair removal, treatment of vascular lesions, acne treatment, skin toning, rejuvenation, and the removal of epidermal pigments for spots, freckles, and tattoos. This expansion into laser therapy further establishes the company's versatility and commitment to offering comprehensive dermatological solutions.
To compliment its primary product offerings, Sensus Healthcare also provides essential disposable accessories such as lead shielding replacements and radiation safety items, including aprons and eye shields. Additionally, they offer ultrasound probe film and disposable applicator tips, ensuring treatments are conducted with the highest standards of safety and hygiene for treating various sized lesions across different body areas.